Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript March 11, 2025Voyager Therapeutics, Inc. misses on earnings expectations.
Voyager Therapeutics Inc. (VYGR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 5,396,000 | $30,595,320 | +4% | 0.41% |
| 2. | EcoR1 Capital Oleg Nodelman | 3,917,546 | $22,212,486 | 0.83% | |
| 3. | Farallon Capital Thomas Steyer | 2,570,700 | $14,575,869 | +13% | 0.07% |
| 4. | Vestal Point Capital Ryan Wilder | 1,230,000 | $6,974,100 | +152% | 0.41% |
| 5. | Great Point Partners Jeffrey Jay And David Kroin | 826,751 | $4,687,678 | -14% | 2.2% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.88 | 4,395,588 | Large Shareholder | 8,575,316 | 2023-02-23 | Filing | |
| $5.66 | 376,000 | Large Shareholder | 4,753,907 | 2022-06-23 | Filing | |
| $5.28 | 101,400 | Large Shareholder | 4,377,907 | 2022-06-21 | Filing | |
| $11.96 | 4,179,728 | Large Shareholder | 4,179,728 | 2019-03-12 | Filing | |
| $19.39 | 3,000 | Director | 76,588 | 2018-09-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.26 | 3,305 | Officer | 77,718 | 2025-02-20 | Filing | |
| $4.24 | 11,702 | Officer, Director | 296,816 | 2025-02-20 | Filing | |
| $4.25 | 3,894 | Officer | 98,397 | 2025-02-20 | Filing | |
| $4.45 | 5,413 | Officer | 81,023 | 2025-02-11 | Filing | |
| $4.45 | 6,950 | Officer | 102,291 | 2025-02-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,356,789 | $30,372,993 | 0% | |
| 2. | 3,215,441 | $18,231,551 | 0% | |
| 3. | 1,380,615 | $7,827,748 | 0% | |
| 4. | 1,084,238 | $6,148,955 | 0% | |
| 5. | 1,058,378 | $5,944,668 | 0.07% |
News See All
10 Cheap Biotech Stocks to Invest in Now
Biotechnology stocks are among the most volatile in the market due to their high risk.
10 Best Gene Therapy Stocks to Buy Right Now
Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Voyager Therapeutics Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Voyager Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time all participants are in a listen-only mode.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Voyager Therapeutics First Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please note that today's conference is being recorded.
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Earnings Call Transcript
Voyager Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.25, expectations were $-0.59. Voyager Therapeutics, Inc.
12 Best Healthcare Stocks For the Long-Term
In this piece, we will take a look at the 12 best healthcare stocks for the long term.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Voyager Therapeutics Third Quarter 2023 Conference Call. All participants are now in a listen-only mode.
Billionaire Hedge Funds
